STTCOMP NTI FA LONG MC $96.32M Cash $14.5M NTI Today Announced:...

STTCOMP NTI FA LONG
MC $96.32M
Cash $14.5M

NTI Today Announced:

Neurotech Phase II/III Autism Trial Successfully Meets Primary Endpoint
https://www.investi.com.au/api/announcements/nti/3e87a498-65a.pdf

And

Neurotech Reports Positive Top-Line Phase I/II Rett Syndrome Clinical Trial Results
https://www.investi.com.au/api/announcements/nti/6b645e01-525.pdf

To have 2 sets of good results is excellent news for any company.

Completion of Phase II Trial Results is often the stage companies make Partnerships,
Or are complete Take-Overs are made by Big Pharma Companies.

The fact that one of these was a Phase II/III is even better.

The stage after Phase III is FDA Approval,
After which sales of the product can begin.

The Autism Market is a very large and growing market.
The global autism spectrum disorder therapeutics market is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, at a CAGR of 7.9%
https://www.fortunebusinessinsights...-spectrum-disorder-therapeutics-market-101207

The global Autism Spectrum Disorders market was valued at $27.3 billion in 2021,
and is projected to reach $43.2 billion by 2031

A Product that can treat it would be valued at many Billions of Dollars.

NTI has shown excellent results and has completed Phase II/ III Human Trials,
Which is the Ideal Time for a Big Pharma Co. to make a Partnership or takeover offer.

NTI has an MC of $96 Million,

Giving a very Significant potential upside,
As well as that this stage is the usual time for Partnerships,
And Outright Take-Over Offers to be made.
Seems like a good time for being tipped in the STT Comp !!!!